Edwards Lifesciences Settles FTC Charges for Bypassing Antitrust Review
Edwards Lifesciences will pay $10 million to settle Federal Trade Commission (FTC) charges related to its acquisition of JC Medical from Genesis MedTech without complying with the Hart-Scott-Rodino Act. The settlement resolves allegations that Edwards and Genesis structured a deal below the reporting threshold, avoiding mandatory antitrust review.
Tickers: $EW
Topics: FTC Hart-Scott-Rodino Act M&A MedTech